Compared with other plant-derived anticancer agents, CS&Z targets the RPL5–c-Myc axis in colorectal cancer and also potentiates the effects of conventional chemotherapeutics, offering a potentially therapeutic advantage. Here, RPL5 is linked to colorectal cancer.